|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nutritional and health benefits of semi-elemental diets: A comprehensive summary of the literature显示文摘AIM:To critically review and summarize the literature on nutritional and health outcomes of semi-elemental formulations on various nutritionally vulnerable patient populations who are unable to achieve adequate nutrition from standard oral diets.METHODS:We conducted a comprehensive literature search of Pubmed and Embase databases.We manually screened articles that examined nutritional and health outcomes(e.g.,growth,disease activity,gastrointestinal impairment,mortality,and economic impact)among various patient groups receiving semi-elemental diets.This review focused on full-text articles of randomized controlled clinical trials and other intervention studies,but pertinent abstracts and case studies were also included.Results pertaining primarily to tolerance,digestion,and absorption were summarized for each patient population in this systematic review.RESULTS:Results pertaining primarily to tolerance,digestion,and absorption were summarized for each patient population.The efficacy of semi-elemental whey hydrolyzed protein(WHP)diet have been reported in various nutritionally high risk patient populations including-Crohn’s disease,short bowel syndrome,acute and chronic pancreatitis,cerebral palsy,cystic fibrosis,cerebrovascular accidents,human immunodeficiency virus,critically ill,and geriatrics.Collectively,the evidence from the medical literature indicates that feeding with a semi-elemental diet performs as well or better than parenteral or amino acid based diets in terms of toler-ance,digestion,and nutrient assimilation measures across various disease conditions.CONCLUSION:Based on this comprehensive review of the literature,patient populations who have difficulty digesting or absorbing standard diets may be able to achieve improved health and nutritional outcomes through the use of semi-elemental WHP diets. | Dominik D Alexander Lauren C Bylsma Laura Elkayam Douglas L Nguyen | 2016 | World Journal of Gastrointestinal Pharmacology and Therapeutics2016，7，2： | 3 |
| 2 | Gangrenous cholecystitis: A silent but potential fatal disease in patients with diabetic neuropathy. A case report显示文摘Gangrenous cholecystitis(GC) is a severe and potentially deadly complication of acute cholecystitis. We present a 83-year-old gentleman with a past medical history of type 2 diabetes mellitus with significant associated neuropathy, presenting to a community hospital in a major metropolitan area with 10 days nausea and vomiting and a benign abdominal exam. While the patient was admitted for hyperglycemia, he was subsequently found to have severe GC requiring urgent surgical intervention. | Melorin Mehrzad Charles C Jehle Lauren O Roussel Raman Mehrzad | 2018 | World Journal of Clinical Cases2018，6，15： | 3 |
| 3 | Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas显示文摘Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significant increase in research directed towards identifying potential biomarkers that can be used to diagnose and provide prognostic information for pancreatic cancer. These markers can be used clinically to optimize and personalize therapy for individual patients. In this review, we focused on 3 biomarkers involved in the DNA damage response pathway and the necroptosis pathway: Chromodomainhelicase-DNA binding protein 5, chromodomain-helicaseDNA binding protein 7, and mixed lineage kinase domain-like protein. The aim of this article is to review present literature provided for these biomarkers and current studies in which their effectiveness as prognostic biomarkers are analyzed in order to determine their future use as biomarkers in clinical medicine. Based on the data presented, these biomarkers warrant further investigation,and should be validated in future studies. | Crystal S Seldon Lauren E Colbert William A Hall Sarah B Fisher David S Yu Jerome C Landry | 2016 | World Journal of Gastrointestinal Oncology2016，8，4： | 2 |
| 4 | Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus显示文摘 | Florine Kastelein Katharina Biermann Ewout W Steyerberg Joanne Verheij Marit Kalisvaart Leendert H J Looijenga Hans A Stoop Laurens Walter Ernst J Kuipers Manon C W Spaander Marco J Bruno | 2013 | Gut2013，，12： | 2 |
| 5 | Hydrogen peroxide fluxes and compartmentalization inside growing Escherichia coli 显示文摘 | Lauren C S James A I | 2001 | J Bacteriol2001，183，24： | 1 |
| 6 | Cross-cultural differences in test perceptions: Women in Kuwait and the United States Journal of Cross-Cultural Psychology 显示文摘 | Jerrell C Cassady Ayoub Mohammed Lauren Mathieu | 2004 | Thousand oaks:2004，35，6： | 1 |
| 7 | Differential Diagnosis of infantile hemangiomas显示文摘 | Lauren C Garzon MC | | 0，，08： | 1 |
| 8 | Management of radial head fractures:current concepts显示文摘 | Laurens Kaas Jesse B Jupiter C | | 0，，01： | 1 |
| 9 | Management of radial head fractures: current concepts 显示文摘 | Laurens Kaas Jesse B Jupiter C | 2011 | Shoulder & Elbow2011，3，： | 1 |
| 10 | Establishment of a bioenergy-focused microalgal culture collection显示文摘 | ELLIOTT L G FEEHAN C LAURENS L M L | 2012 | Algal Research2012，1，2： | 1 |
| 11 | Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis显示文摘 | Lauren C Robey D Amy A | 2006 | Exp Neurol2006，198，2： | 1 |
| 12 | Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symp- tomatic atherosclerosis显示文摘 | Lauren C Jeffrey A Sumit R | 2004 | CMAJ2004，171，10： | 1 |
| 13 | Assessment of functional recovery and axonal sprouting in oligodendrocyte myelin glycoprotein(OMgp) null mice after spinal cord injury显示文摘 | Benxiu J Lauren C | 2008 | Mol Cell Neurosci2008，39，2： | 1 |
| 14 | Optimizing bioavailability in the treatment of Parkinson's disease显示文摘 | Lauren C Seeberger Robert A | 2007 | Neuropharmacdogy2007，53，7： | 1 |
| 15 | Gas chromatographic-mass spectrometric confirmation of atractyloside in a patient poisoned with Callilepis laureola显示文摘 | Laurens J B Bekker L C Steenkamp V | 2001 | J Chromatogr B2001，765，2： | 1 |
| 16 | Sensory Properties of Ginseng Solutions Modified by Masking Agents 显示文摘 | Lauren C Tamamoto Shelly J Schmidt Soo-Yeun Lee | 2010 | Journal of Food Science2010，75，7： | 1 |
| 17 | Nitriding of titanium under CW CO2 laser radiation显示文摘 | Laurens P L'enfant H Sainte Catherine M C | 1997 | Thin Solid Films1997，293，： | 1 |
| 18 | Improving hilt report fo CUS and consistency with the situation, background, assess- ment, recommendation protocol 显示文摘 | Paul C Mary T G Lauren Y J | 2013 | Journal of Nursing Ad- ministration2013，43，78： | 1 |
| 19 | Anterior versus posterior spinal instrumentation for the treatment of thoracolumbar curves in adolescent idiopathic scoliosis显示文摘 | David L Lauren F Kasey C | 2003 | Spine2003，28，5： | 1 |
| 20 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员